NCT07478809

A Retrospective Real-World Study Based on RATIONALE-307

Long-Term Efficacy and Safety Analysis of First-Line Tislelizumab in Patients With Advanced Squamous NSCLC: a Retrospective Real-World Study Based on RATIONALE-307

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 109 (estimated)
• Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.

Conditions

• NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

Type	Name	Description
OTHER	No intervention	No intervention

Timeline

• Start date: 2026-02-28
• Primary completion: 2026-12-31
• Completion: 2027-12-31
• First posted: 2026-03-18
• Last updated: 2026-03-27

Locations

1 site across 1 country: China